# MOTS-c: Current Availability at Telos Rx

**By TelosRX Editorial Team** · 2026-09-21

**MOTS-c is a mitochondrial-derived peptide studied for its role in cellular energy metabolism, and telos rx does not currently offer it for compounding while the peptide remains under internal review.**

What to know

MOTS-c is encoded within mitochondrial DNA and has drawn research interest for its possible link to how cells generate and use energy. It is not part of the telos rx compounding program today, and there is no confirmed date for when, or if, that will change. This page exists to give you an honest, current answer rather than vague marketing language.

## What MOTS-c is

MOTS-c is a small peptide derived from a region of mitochondrial DNA rather than the nuclear genome most peptides are encoded by. Mitochondria are the structures inside cells responsible for converting nutrients into usable energy. Researchers have been interested in peptides like MOTS-c because they appear to participate in signaling pathways connected to metabolism and cellular stress responses.

Interest in MOTS-c grew alongside broader research into mitochondrial-derived peptides as a category, a relatively young area of peptide science compared to growth-hormone-related or repair-focused peptides that have a longer research history. Much of the published work so far involves laboratory and animal models, with human research still developing. You can browse the current published research yourself through the [NIH's PMC database of MOTS-c studies](https://www.ncbi.nlm.nih.gov/pmc/?term=MOTS-c). It is a useful way to see what has actually been established versus what remains preliminary.

The compound sits at an earlier stage of research and regulatory clarity than some other peptides. Because of that, it is reasonable for a patient to ask direct questions about where a given pharmacy or telehealth provider actually stands on it, rather than assuming availability.

## Why telos rx does not currently offer MOTS-c

telos rx does not currently offer MOTS-c for compounding. The reason is straightforward: telos rx is reviewing this peptide for its program and has not added it to the current compounding lineup. A 2026 Pharmacy Compounding Advisory Committee (PCAC) review issued non-binding recommendations covering several research peptides. A recommendation from that committee is not the same as regulatory approval, and it does not by itself clear a peptide for routine compounding.

Because that distinction matters, telos rx has chosen not to add MOTS-c to its program until the picture is clearer. You can read more about [telos rx's current status on MOTS-c](https://www.telosrx.com/pages/mots-c) directly on its informational page, which is kept up to date as the situation evolves.

This is not a statement about long-term interest one way or the other. It is simply where things stand today, described plainly so you can make informed decisions instead of guessing.

**Key takeaway:** MOTS-c is a mitochondrial-derived peptide under active research, not a peptide telos rx currently compounds, because it is still under internal review and has not been added to the program.

## How research peptides like this typically move through a compounding pharmacy's review

Compounding pharmacies generally do not add a peptide to their catalog the moment early research or a committee discussion appears. A pharmacy has to weigh several factors. These include whether the raw material can be sourced from a quality-controlled supplier, whether enough safety and dosing information exists, and whether current federal guidance treats the substance as appropriate for compounding.

A non-binding PCAC recommendation is one input into that process, not a green light. Committees like PCAC advise the FDA, and the FDA itself has to weigh that advice before any formal rule change occurs. The FDA's own overview of how compounding regulation works, available at its [compounding questions and answers page](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers), is a useful starting point for understanding that process. Until a final rule or clear regulatory pathway exists, a responsible pharmacy program is likely to treat a peptide like MOTS-c as unresolved rather than ready.

That is the position telos rx has taken. It is a cautious stance by design, and it means the honest answer today is that MOTS-c is not available here, without a promised timeline attached to it.

## What "under review" actually means

When telos rx describes a peptide as under review, it means the internal team is tracking the regulatory and scientific landscape around that compound. It has not committed to adding MOTS-c to the program. It does not mean a launch is scheduled, and it does not mean the peptide is being tested with patients in any informal way.

"Under review" is also different from being on a waitlist. There is no queue to join and no signup that moves you closer to access, because access is not something telos rx controls unilaterally. It depends on the broader regulatory environment around compounded mitochondrial peptides settling into something clearer than it is today.

If and when telos rx does reach a decision about MOTS-c, that information would appear on the product's dedicated page rather than being announced through vague hints elsewhere on the site. Checking that page directly is the most reliable way to get a current answer, since program status can change as regulatory guidance develops.

## Where mitochondrial energy support fits into a broader peptide conversation

Cellular energy metabolism is a legitimate and growing area of interest in peptide and wellness research generally. Mitochondrial function touches everything from how tissue repairs itself to how the body handles physical stress, which is part of why mitochondrial-derived peptides like MOTS-c have attracted attention beyond focused scientific circles.

That broader interest is worth separating from any specific peptide's individual regulatory status, though. A category can be scientifically interesting while a single compound within it, like MOTS-c, still sits in a gray zone that keeps it out of a given pharmacy's compounding program.

## Questions worth asking any peptide source

Whether you are looking into MOTS-c or any other peptide, it helps to know what a trustworthy source looks like before you commit to one. A legitimate telehealth or pharmacy partner should clearly state whether a given compound is currently in its program. It should not lean on marketing language that implies availability without confirming it.

It is also worth asking who reviews new peptide additions, what pharmacy actually prepares the compound, and whether that pharmacy carries independent certification. These are simple questions, and a source with nothing to hide should answer them plainly rather than deflecting.

At telos rx, the answer for MOTS-c specifically is direct: it is not part of the program today. That kind of plain statement, even when the answer is "not yet," is part of how a compounding pharmacy earns trust over time.

## Staying informed without relying on rumors

Peptide communities online move quickly, and claims about a compound's regulatory status can spread well before anything is confirmed. A forum post or social media claim that a peptide has been "approved" is not the same as an FDA rule change. A single non-binding committee recommendation does not settle the matter either.

The most reliable way to track MOTS-c's status is to check primary sources directly. That means the FDA's own compounding guidance for regulatory questions, and a pharmacy's own dedicated product page, like the one telos rx maintains, for that specific provider's current program status.

Patience here is less about waiting passively and more about avoiding decisions based on incomplete or premature information. A peptide that seems close to available based on secondhand claims may still be months or years from any actual regulatory clarity.

## Which is right for you

Your interest in MOTS-c may come from wanting to support cellular energy and metabolic function. If so, it is worth knowing that telos rx does currently offer [NAD+ nasal spray](https://www.telosrx.com/pages/nad-nasal-spray), a different protocol aimed at a related area of cellular energy metabolism through NAD+ pathways. It is not the same compound or mechanism as MOTS-c, and it should not be mistaken for a substitute. It is, however, a real and available option today if that general category interests you.

telos rx also currently offers [BPC-157](https://www.telosrx.com/pages/bpc-157) for tissue-support goals, [sermorelin](https://www.telosrx.com/pages/sermorelin) for growth-hormone-related goals, and [PT-141](https://www.telosrx.com/pages/pt-141) for a separate use case entirely. None of these replace MOTS-c, but each is a real option you can evaluate with a licensed provider right now.

[Start your NAD+ visit →](https://start.telosrx.com/start-online-visit/peptides)

## Frequently Asked Questions

### Is MOTS-c available at telos rx right now?

No. telos rx does not currently offer MOTS-c for compounding because the peptide is still under internal review and has not been added to the program.

### What is MOTS-c?

MOTS-c is a peptide encoded by mitochondrial DNA that researchers have studied for its possible role in cellular energy metabolism and stress response signaling.

### Did the 2026 PCAC review approve MOTS-c for compounding?

No. The 2026 PCAC review issued non-binding recommendations regarding several research peptides. A recommendation is advice to regulators, not an approval, and it does not clear a peptide for routine compounding on its own.

### Will telos rx add MOTS-c in the future?

There is no confirmed timeline. telos rx is reviewing MOTS-c and will update its dedicated MOTS-c page if the program status changes.

### Is there an alternative available at telos rx today for cellular energy support?

telos rx currently offers NAD+ nasal spray, which addresses cellular energy metabolism through a different pathway than MOTS-c. It is a separate protocol, not a substitute for MOTS-c specifically.

### Where can I check telos rx's current status on MOTS-c?

telos rx keeps an informational page dedicated to MOTS-c that reflects its current program status, and that page is the most reliable place to check for updates.

_TelosRX is LegitScript-certified. Compounded medication is not FDA-approved and is prepared under federal compounding regulations. This article is general information, not medical advice, and does not replace guidance from your own provider. Approval is subject to evaluation by a licensed provider, and approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service._

Questions about telos rx's current peptide program? [See available peptides](https://telosrx.com/pages/peptides) or start your evaluation at [TelosRX](https://telosrx.com).

**Tags:** mitochondrial health, mots-c, peptides

---

> Source: [Telos RX](https://www.telosrx.com/blogs/glp1/mots-c-current-availability-at-telos-rx)